Pharma Tech Outlook: Pharma Tech Magazine

Inmunotek: Pushing the Boundaries of Immunotherapy

Top 10 Immunotherapy Solution Companies in Europe - 2020


Ever since discovering immunotherapy as a powerful tool to help patients fight the dreadful battle against cancer, several kinds of research and developments have taken place to bolster its performance. The growth of this market worldwide, including Europe, is majorly attributed to the rising prevalence of target diseases, increasing demand for monoclonal antibodies and biosimilars, and many more. Currently, clinicians are heavily investing in immunotherapy drugs over the conventional treatments. Additionally, Monoclonal antibodies are acting as the vital weapon of the immunotherapy toolkit to recruit NK cells, a powerful replacement to the average CD8+ T cells. NK cells’ main advantage lies in their capacity to kill any malignant target cell; all it needs is the right balance of activating and inhibitory receptors with the perfect stimulation to engage. Efficiently distinguishing between transformed or virally infected cells and normal cells without the need for prior sensitization with an antigen, NK cells kill abnormal cells before specific immunity develops. An innate cytotoxic immune cell, NK cells clear out the tumor development process/area and lyse target cells following the engagement of inhibitory and activating receptors. Thereby, owing to its precision and robust performance, monoclonal antibodies coupled with NK cells are becoming the standard immunotherapy care for treating different types of cancer.

In the wake of such drastic transitions, we have compiled this issue of Pharma Tech Outlook in order to assist organisations in the task of finding accomplished solution providers to help them navigate the immunotherapy realm. In this edition, we have listed the top 10 immunotherapy solution providers 2020 in Europe to highlight the companies that can escalate the chances of your growth. Equipped with innovative technological capabilities, these enlisted solution providers are transforming the immunotherapy landscape at the cloverleaf of various disruptive technologies. Besides, the magazine comprises insights from subject-matter experts, CIOs, and CXOs in the medical sector on the latest industry trends, best practices, recent innovations, and highlights their expertise. We hope this issue of Pharma Tech Outlook helps you build the partnership you and your organisation need to foster an environment driven by robust and efficient technology.

We present to you Pharma Tech Outlook’s, “Top 10 Immunotherapy Solution Providers in Europe - 2020.”

    Top Immunotherapy Solution Companies in Europe

  • Committed to improving outcomes for cancer patients for nearly two decades, Affimed—a scientific team devoted to unlocking the potential of the innate immune system with unique expertise in innate immunity and innate cell engager-based medicines. The company aims to help patients and healthcare providers overcome limitations and challenges faced by current immune-oncology therapies by arming the body’s innate immune systems in the fight against cancer and other life-threatening diseases

  • Glycostem is an international organization focused on the development of stem cell-derived Natural Killer cells (NK cells) as a medicinal asset in the fight against cancer. Since its founding in 2007, the Dutch organization has been focused on tapping into the potential of stem cell-derived NK cells as an asset in the fight against cancer. The company, in collaboration with various partners, has also developed a second generation of Chimeric Antigen Receptor (CAR) NK cell products that enhance tumor targeting, and have fewer side effects compared to current CAR-T treatments

  • Inmunotek is a pharmaceutical laboratory based in Madrid that develops, manufactures, and markets products for the diagnosis and treatment of diseases in the field of allergy and immunology for human and veterinary pathology. The company’s primary focus is on research, development, manufacturing, and marketing of allergy and immunology products, including immunotherapies and diagnostics. Especially, Inmunotek’s R&D program is continually innovating and improving its allergy and mucosal vaccines to prevent recurrent infections, while also enhancing vaccine adjuvants and cancer vaccines

  • AltraBio


    AltraBio is an R&D company for analysis and interpretation of biomedical data in both preclinical and clinical development and for development of analytic and predictive tools. AltraBio is particularly focused on OMICS technologies (genomics, transcriptomics, proteomics etc.) and flow/mass cytometry with the goal of unlocking the value captured in large scale data set generated in life science experimental studies. AltraBio's work flow covers the part of the R&D process following the generation of data in the experiment

  • Cellectis


    Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its proprietary gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells



    ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs

  • HiFiBiO Therapeutics

    HiFiBiO Therapeutics

    HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease. The company integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. In addition, HiFiBiO Therapeutics aspires to benefit patients through open-innovation partnerships with industry and academia

  • Invectys


    Founded in 2010 and based in Paris, Invectys is a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers. Invectys exploits a novel approach to mobilizing and restoring the anti-tumor capacity of the immune system of cancer patients. This allows targeting practically all cancers. Invectys converged on the universal tumor antigen telomerase that is critical to uncontrolled cell growth

  • OncoImmunity AS

    OncoImmunity AS

    OncoImmunity AS is a Norwegian company established to develop bioinformatics software that has the ability to empower precision cancer immunotherapy, and thus improve the outlook for patients with late-stage disease. They develop machine-learning methods, accessible online, applied to genomics data for tumor immune profiling. The company has just successfully completed a funding round and has attracted significant investment from both life science and software investors

  • OSE Immunotherapeutics

    OSE Immunotherapeutics

    OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmmune diseases. The company utilizes several scientific and technological approaches including neoepitopes and agonist/antagonist monoclonal antibodies, all ideally positioned to fight cancer and autoimmune diseases. Their first-in-class pipeline offers a diversified risk profile, ranging from registrational to clinical stage to R&D